Mantle Cell Lymphoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 307 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Mantle Cell Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H2 2014', provides an overview of the Mantle Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Mantle Cell Lymphoma Overview 8
Therapeutics Development 9
Pipeline Products for Mantle Cell Lymphoma - Overview 9
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 10
Mantle Cell Lymphoma - Therapeutics under Development by Companies 11
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 15
Mantle Cell Lymphoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Mantle Cell Lymphoma - Products under Development by Companies 20
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 23
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 24
Johnson & Johnson 24
Amgen Inc. 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
MedImmune, LLC 28
Gilead Sciences, Inc. 29
Merck & Co., Inc. 30
Infinity Pharmaceuticals, Inc. 31
Millennium Pharmaceuticals, Inc. 32
Novartis AG 33
Astellas Pharma Inc. 34
ImmunoGen, Inc. 35
Pfizer Inc. 36
Astex Pharmaceuticals, Inc. 37
Teva Pharmaceutical Industries Limited 38
Celgene Corporation 39
Onyx Pharmaceuticals, Inc. 40
Bayer AG 41
Incyte Corporation 42
Celldex Therapeutics, Inc. 43
Accentia Biopharmaceuticals, Inc. 44
Portola Pharmaceuticals, Inc. 45
Pharmacyclics, Inc. 46
Senesco Technologies, Inc. 47
Affimed Therapeutics AG 48
Memgen, LLC. 49
Stemline Therapeutics, Inc. 50
Onconova Therapeutics, Inc. 51
LFB S.A. 52
Advancell 53
Selvita S.A 54
Frost Biologic, Inc. 55
Karyopharm Therapeutics, Inc. 56
Lypro Biosciences, Inc. 57
Kite Pharma, Inc. 58
AbbVie Inc. 59
Inatherys 60
Mantle Cell Lymphoma - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Target 62
Assessment by Mechanism of Action 66
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 75
ibrutinib - Drug Profile 75
bortezomib - Drug Profile 80
bortezomib - Drug Profile 85
bendamustine hydrochloride - Drug Profile 90
ixazomib citrate - Drug Profile 92
ibrutinib - Drug Profile 94
abexinostat hydrochloride - Drug Profile 99
agatolimod sodium - Drug Profile 101
dasiprotimut-T - Drug Profile 104
AT-7519 - Drug Profile 106
carfilzomib - Drug Profile 109
idelalisib - Drug Profile 112
ISF-35 - Drug Profile 114
tisagenlecleucel-T - Drug Profile 116
vorinostat - Drug Profile 118
buparlisib hydrochloride - Drug Profile 121
lenalidomide - Drug Profile 125
LY-2835219 - Drug Profile 128
ublituximab - Drug Profile 129
GS-9973 - Drug Profile 131
moxetumomab pasudotox - Drug Profile 132
SNS-01T - Drug Profile 134
PRT-2070 - Drug Profile 135
Cell Therapy to Inhibit CD19 for Oncology - Drug Profile 136
Cell Therapy to Target CD19 for Mantle Cell Lymphoma - Drug Profile 137
CEP-9722 - Drug Profile 138
pevonedistat hydrochloride - Drug Profile 139
blinatumomab - Drug Profile 141
varlilumab - Drug Profile 144
rigosertib sodium - Drug Profile 146
AFM-11 - Drug Profile 150
copanlisib - Drug Profile 151
palbociclib - Drug Profile 154
NSC-678515 - Drug Profile 157
LEE-011 - Drug Profile 158
duvelisib - Drug Profile 160
AMG-319 - Drug Profile 162
IMGN-529 - Drug Profile 163
venetoclax - Drug Profile 164
selinexor - Drug Profile 167
KTE-C19 CAR - Drug Profile 169
INCB-40093 - Drug Profile 170
daratumumab - Drug Profile 171
acadesine - Drug Profile 173
Small Molecule to Inhibit RNA for Cancer - Drug Profile 175
SEL-120 - Drug Profile 176
BLyS-gel - Drug Profile 177
INA-01 - Drug Profile 178
13197 - Drug Profile 179
FROST-400 - Drug Profile 181
SL-101 - Drug Profile 182
tretinoin - Drug Profile 183
CC-2141 - Drug Profile 185
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 186
Mantle Cell Lymphoma - Recent Pipeline Updates 187
Mantle Cell Lymphoma - Dormant Projects 290
Mantle Cell Lymphoma - Discontinued Products 291
Mantle Cell Lymphoma - Product Development Milestones 292
Featured News & Press Releases 292
Appendix 302
Methodology 302
Coverage 302
Secondary Research 302
Primary Research 302
Expert Panel Validation 302
Contact Us 303
Disclaimer 303

List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H2 2014 13
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Development by Companies, H2 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Late Stage Development, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 22
Comparative Analysis by Early Stage Development, H2 2014 23
Products under Development by Companies, H2 2014 24
Products under Development by Companies, H2 2014 (Contd..1) 25
Products under Development by Companies, H2 2014 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2014 27
Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2014 28
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2014 29
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2014 30
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H2 2014 31
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2014 33
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 34
Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 35
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 36
Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2014 37
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2014 38
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2014 39
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H2 2014 40
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 41
Mantle Cell Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 42
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2014 43
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 44
Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2014 45
Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2014 46
Mantle Cell Lymphoma - Pipeline by Celldex Therapeutics, Inc., H2 2014 47
Mantle Cell Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H2 2014 48
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 50
Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014 52
Mantle Cell Lymphoma - Pipeline by Memgen, LLC., H2 2014 53
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2014 54
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2014 55
Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2014 56
Mantle Cell Lymphoma - Pipeline by Advancell, H2 2014 57
Mantle Cell Lymphoma - Pipeline by Selvita S.A, H2 2014 58
Mantle Cell Lymphoma - Pipeline by Frost Biologic, Inc., H2 2014 59
Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 60
Mantle Cell Lymphoma - Pipeline by Lypro Biosciences, Inc., H2 2014 61
Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2014 62
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H2 2014 63
Mantle Cell Lymphoma - Pipeline by Inatherys, H2 2014 64
Assessment by Monotherapy Products, H2 2014 65
Number of Products by Stage and Target, H2 2014 68
Number of Products by Stage and Mechanism of Action, H2 2014 72
Number of Products by Stage and Route of Administration, H2 2014 75
Number of Products by Stage and Molecule Type, H2 2014 78
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 191
Mantle Cell Lymphoma - Dormant Projects, H2 2014 294
Mantle Cell Lymphoma - Discontinued Products, H2 2014 295